Patent · US Active

Human cytomegalovirus gB polypeptide

US11629172B2 · kind B2 · utility

0Cited by

4References

14Claims

0Family size

Assignee

PFIZER INC. · US

Inventors

Philip Dormitzer · Cambridge, US
Ye Che · Groton, US
Xiaoyuan Sherry Chi · Tenafly, US
Seungil Han · Mystic, US
Kyle P. HEIM · Boulder, US
Thomas R. Jones · Gaylord, US
Yuhang Liu · South Glastonbury, US
Xiayang Qiu · Mystic, US
Xinzhen Yang · Woodcliff Lake, US
Xiaojie Yao · East Lyme, US
Matthew Curtis Griffor · Preston, US
Jennifer Anne Nicki · Gales Ferry, US

Key dates

Filing date	Dec 19, 2019
Grant date	Apr 18, 2023
Priority date	—
Expiry date	Dec 19, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.